· Published by Health Canada · Official notice
This is duplicated text of a letter from Hospira Healthcare Corporation.
Contact the company for a copy of any references, attachments or enclosures.
June 26, 2012
Dear Healthcare Professional,
Please distribute to relevant Departments (Surgery, Emergency Medicine, Pharmacy, Paediatrics, Geriatrics, Internal Medicine, Oncology, Nursing, Intensive Care and/or other Departments as required), and other involved professional staff and post this Notice in your institution.
Subject: Glass Vial Defects for 3 Lots of Paclitaxel for Injection, 300mg/50mL, (DIN: 02296624)
Hospira Healthcare Corporation, in consultation with Health Canada, would like to inform you that complaints were received from customers outside of Canada of visible vial defects for multiple products. The vial defects may manifest as particles embedded in the glass vial, as rust-like marks on the vial or as particles in the solution. The three lots of Paclitaxel identified below and distributed in Canada were manufactured using the same affected empty glass vial, however, no defects or complaints have been reported to date for these lots. Paclitaxel for Injection is a clear colorless to slightly yellow viscous solution and is indicated in the treatment of carcinoma of the ovary, breast or lung.
Affected lots of Paclitaxel:
There are three potential scenarios for this defect:
Hospira has not received any reports of adverse events associated with these lots of Paclitaxel from its customers. An investigation is ongoing to determine corrective and/or preventive actions. Hospira commits to continue monitoring all product defect reports (complaints and retains). Additionally, Hospira will not release further inventory from these 3 lots of Paclitaxel. A shortage situation is not anticipated.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any cases of serious specific adverse reaction or other serious or unexpected adverse reactions in patients receiving Paclitaxel for Injection (300mg/50mL) should be reported to Hospira Healthcare Corporation or Health Canada at the following addresses:
Hospira Healthcare Corporation
Complaint & Safety Department
1111 Dr.-Frederik-Philips, Suite 600
Saint-Laurent (Québec) H4M 2X6
To report an Adverse Reaction, consumers and health professionals may call toll free :
Telephone: 1-866-488-6088 Option 6
Fax: 1-877-906-0208
ProductcomplaintsCA@hospira.com
To correct your mailing address or fax number, contact Hospira Healthcare Corporation.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Lead Directorate: Health and Product and Food Branch Inspectorate (HPFBI)
E-mail: DCVIU_UVECM@hc-sc.gc.ca
Telephone: 1-800-267-9675
Fax: 1-613-954-0941
Sincerely,
original signed by
Rania Al-Ammar
Regional Director, Commercial Quality
Hospira Healthcare Corporation